213 related articles for article (PubMed ID: 37014523)
1. Ewing Sarcoma Drug Therapy: Current Standard of Care and Emerging Agents.
Setty BA; Gikandi A; DuBois SG
Paediatr Drugs; 2023 Jul; 25(4):389-397. PubMed ID: 37014523
[TBL] [Abstract][Full Text] [Related]
2. Pharmaceutical Interference of the EWS-FLI1-driven Transcriptome By Cotargeting H3K27ac and RNA Polymerase Activity in Ewing Sarcoma.
Heisey DAR; Jacob S; Lochmann TL; Kurupi R; Ghotra MS; Calbert ML; Shende M; Maves YK; Koblinski JE; Dozmorov MG; Boikos SA; Benes CH; Faber AC
Mol Cancer Ther; 2021 Oct; 20(10):1868-1879. PubMed ID: 34315769
[TBL] [Abstract][Full Text] [Related]
3. Ewing's sarcoma: standard and experimental treatment options.
Subbiah V; Anderson P; Lazar AJ; Burdett E; Raymond K; Ludwig JA
Curr Treat Options Oncol; 2009 Apr; 10(1-2):126-40. PubMed ID: 19533369
[TBL] [Abstract][Full Text] [Related]
4. BET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma.
Loganathan SN; Tang N; Fleming JT; Ma Y; Guo Y; Borinstein SC; Chiang C; Wang J
Oncotarget; 2016 Jul; 7(28):43504-43517. PubMed ID: 27259270
[TBL] [Abstract][Full Text] [Related]
5. New Insights about the Wnt/β-Catenin Signaling Pathway in Primary Bone Tumors and Their Microenvironment: A Promising Target to Develop Therapeutic Strategies?
Danieau G; Morice S; Rédini F; Verrecchia F; Royer BB
Int J Mol Sci; 2019 Jul; 20(15):. PubMed ID: 31370265
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic opportunities in Ewing sarcoma: EWS-FLI inhibition via LSD1 targeting.
Theisen ER; Pishas KI; Saund RS; Lessnick SL
Oncotarget; 2016 Apr; 7(14):17616-30. PubMed ID: 26848860
[TBL] [Abstract][Full Text] [Related]
7. Impact of Two Measures of Micrometastatic Disease on Clinical Outcomes in Patients with Newly Diagnosed Ewing Sarcoma: A Report from the Children's Oncology Group.
Vo KT; Edwards JV; Epling CL; Sinclair E; Hawkins DS; Grier HE; Janeway KA; Barnette P; McIlvaine E; Krailo MD; Barkauskas DA; Matthay KK; Womer RB; Gorlick RG; Lessnick SL; Mackall CL; DuBois SG
Clin Cancer Res; 2016 Jul; 22(14):3643-50. PubMed ID: 26861456
[TBL] [Abstract][Full Text] [Related]
8. The clinical heterogeneity of round cell sarcomas with EWSR1/FUS gene fusions: Impact of gene fusion type on clinical features and outcome.
Tsuda Y; Zhang L; Meyers P; Tap WD; Healey JH; Antonescu CR
Genes Chromosomes Cancer; 2020 Sep; 59(9):525-534. PubMed ID: 32362012
[TBL] [Abstract][Full Text] [Related]
9. Targeting the epigenetic readers in Ewing sarcoma inhibits the oncogenic transcription factor EWS/Fli1.
Jacques C; Lamoureux F; Baud'huin M; Rodriguez Calleja L; Quillard T; Amiaud J; Tirode F; Rédini F; Bradner JE; Heymann D; Ory B
Oncotarget; 2016 Apr; 7(17):24125-40. PubMed ID: 27006472
[TBL] [Abstract][Full Text] [Related]
10. Emerging therapies in Ewing sarcoma.
Strauss SJ; Berlanga P; McCabe MG
Curr Opin Oncol; 2024 May; ():. PubMed ID: 38775200
[TBL] [Abstract][Full Text] [Related]
11. Update in treatment and targets in Ewing sarcoma.
Cote GM; Choy E
Hematol Oncol Clin North Am; 2013 Oct; 27(5):1007-19. PubMed ID: 24093173
[TBL] [Abstract][Full Text] [Related]
12. Germline PTPRD mutations in Ewing sarcoma: biologic and clinical implications.
Jiang Y; Janku F; Subbiah V; Angelo LS; Naing A; Anderson PM; Herzog CE; Fu S; Benjamin RS; Kurzrock R
Oncotarget; 2013 Jun; 4(6):884-9. PubMed ID: 23800680
[TBL] [Abstract][Full Text] [Related]
13. Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children's Oncology Group.
Womer RB; West DC; Krailo MD; Dickman PS; Pawel BR; Grier HE; Marcus K; Sailer S; Healey JH; Dormans JP; Weiss AR
J Clin Oncol; 2012 Nov; 30(33):4148-54. PubMed ID: 23091096
[TBL] [Abstract][Full Text] [Related]
14. Functional, chemical genomic, and super-enhancer screening identify sensitivity to cyclin D1/CDK4 pathway inhibition in Ewing sarcoma.
Kennedy AL; Vallurupalli M; Chen L; Crompton B; Cowley G; Vazquez F; Weir BA; Tsherniak A; Parasuraman S; Kim S; Alexe G; Stegmaier K
Oncotarget; 2015 Oct; 6(30):30178-93. PubMed ID: 26337082
[TBL] [Abstract][Full Text] [Related]
15. Primary subcutaneous spindle cell Ewing sarcoma with strong S100 expression and EWSR1-FLI1 fusion: a case report.
Arnold MA; Ballester LY; Pack SD; Abdullaev Z; Merchant M; Tsokos MG
Pediatr Dev Pathol; 2014; 17(4):302-7. PubMed ID: 24735198
[TBL] [Abstract][Full Text] [Related]
16. Poly(ADP-ribose) polymerase inhibitors in Ewing sarcoma.
Vormoor B; Curtin NJ
Curr Opin Oncol; 2014 Jul; 26(4):428-33. PubMed ID: 24840521
[TBL] [Abstract][Full Text] [Related]
17. A novel oncogenic mechanism in Ewing sarcoma involving IGF pathway targeting by EWS/Fli1-regulated microRNAs.
McKinsey EL; Parrish JK; Irwin AE; Niemeyer BF; Kern HB; Birks DK; Jedlicka P
Oncogene; 2011 Dec; 30(49):4910-20. PubMed ID: 21643012
[TBL] [Abstract][Full Text] [Related]
18. Ewing sarcoma of the small bowel: a study of seven cases, including one with the uncommonly reported EWSR1-FEV translocation.
Milione M; Gasparini P; Sozzi G; Mazzaferro V; Ferrari A; Casali PG; Perrone F; Tamborini E; Pellegrinelli A; Gherardi G; Arrigoni G; Collini P; Testi A; De Paoli E; Aiello A; Pilotti S; Pelosi G
Histopathology; 2014 Jun; 64(7):1014-26. PubMed ID: 24898918
[TBL] [Abstract][Full Text] [Related]
19. Targeted therapies for advanced Ewing sarcoma family of tumors.
Jiang Y; Ludwig J; Janku F
Cancer Treat Rev; 2015 May; 41(5):391-400. PubMed ID: 25869102
[TBL] [Abstract][Full Text] [Related]
20. Blocking the road, stopping the engine or killing the driver? Advances in targeting EWS/FLI-1 fusion in Ewing sarcoma as novel therapy.
Kovar H
Expert Opin Ther Targets; 2014 Nov; 18(11):1315-28. PubMed ID: 25162919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
